Mendus AB (publ) (IMMU.ST)
SEK 4.95
(3.02%)
SEK 4.95
(3.02%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 755.95 Million SEK | 21.85% |
| 2022 | 620.38 Million SEK | -13.95% |
| 2021 | 720.98 Million SEK | -1.05% |
| 2020 | 728.66 Million SEK | 139.83% |
| 2019 | 303.82 Million SEK | -32.54% |
| 2018 | 450.37 Million SEK | 82.97% |
| 2017 | 246.14 Million SEK | 102.47% |
| 2016 | 121.56 Million SEK | -21.18% |
| 2015 | 154.23 Million SEK | 117.14% |
| 2014 | 71.03 Million SEK | -35.15% |
| 2013 | 109.53 Million SEK | 310.31% |
| 2012 | 26.69 Million SEK | 187.86% |
| 2011 | 9.27 Million SEK | 48.46% |
| 2010 | 6.24 Million SEK | -18.69% |
| 2009 | 7.68 Million SEK | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 714.93 Million SEK | -5.43% |
| 2024 Q2 | 740.96 Million SEK | 3.64% |
| 2023 Q3 | 807.71 Million SEK | 34.49% |
| 2023 FY | 755.95 Million SEK | 21.85% |
| 2023 Q1 | 615.79 Million SEK | -0.74% |
| 2023 Q4 | 755.95 Million SEK | -6.41% |
| 2023 Q2 | 600.57 Million SEK | -2.47% |
| 2022 Q2 | 685.35 Million SEK | -4.66% |
| 2022 Q3 | 652.22 Million SEK | -4.84% |
| 2022 Q4 | 620.38 Million SEK | -4.88% |
| 2022 FY | 620.38 Million SEK | -13.95% |
| 2022 Q1 | 718.87 Million SEK | -0.29% |
| 2021 Q4 | 720.98 Million SEK | -3.18% |
| 2021 Q1 | 681.98 Million SEK | -6.41% |
| 2021 FY | 720.98 Million SEK | -1.05% |
| 2021 Q2 | 772.52 Million SEK | 13.28% |
| 2021 Q3 | 744.65 Million SEK | -3.61% |
| 2020 Q2 | 242.13 Million SEK | -9.96% |
| 2020 Q1 | 268.91 Million SEK | -11.49% |
| 2020 FY | 728.66 Million SEK | 139.83% |
| 2020 Q3 | 204.19 Million SEK | -15.67% |
| 2020 Q4 | 728.66 Million SEK | 256.85% |
| 2019 Q4 | 303.82 Million SEK | -10.34% |
| 2019 FY | 303.82 Million SEK | -32.54% |
| 2019 Q2 | 370.55 Million SEK | -7.02% |
| 2019 Q3 | 338.87 Million SEK | -8.55% |
| 2019 Q1 | 398.54 Million SEK | -11.51% |
| 2018 Q3 | 138.36 Million SEK | -11.9% |
| 2018 Q2 | 157.06 Million SEK | -10.94% |
| 2018 Q1 | 176.36 Million SEK | -28.35% |
| 2018 FY | 450.37 Million SEK | 82.97% |
| 2018 Q4 | 450.37 Million SEK | 225.49% |
| 2017 Q4 | 246.14 Million SEK | 312.85% |
| 2017 Q3 | 59.62 Million SEK | -24.16% |
| 2017 Q2 | 78.61 Million SEK | -22.93% |
| 2017 Q1 | 102 Million SEK | -16.09% |
| 2017 FY | 246.14 Million SEK | 102.47% |
| 2016 Q1 | 48.63 Million SEK | -11.48% |
| 2016 Q3 | 135.65 Million SEK | -12.05% |
| 2016 Q4 | 121.56 Million SEK | -10.39% |
| 2016 Q2 | 154.23 Million SEK | 217.14% |
| 2016 FY | 121.56 Million SEK | -21.18% |
| 2015 FY | 154.23 Million SEK | 117.14% |
| 2015 Q4 | 54.94 Million SEK | -13.7% |
| 2015 Q1 | 78.5 Million SEK | -12.58% |
| 2015 Q3 | 63.66 Million SEK | -10.37% |
| 2015 Q2 | 71.03 Million SEK | -9.51% |
| 2014 Q4 | 89.79 Million SEK | -9.91% |
| 2014 FY | 71.03 Million SEK | -35.15% |
| 2014 Q3 | 99.67 Million SEK | -9.0% |
| 2014 Q2 | 109.53 Million SEK | 490.44% |
| 2014 Q1 | 18.55 Million SEK | -13.04% |
| 2013 Q3 | - SEK | -100.0% |
| 2013 Q4 | 21.33 Million SEK | 0.0% |
| 2013 Q2 | 26.69 Million SEK | 0.0% |
| 2013 FY | 109.53 Million SEK | 310.31% |
| 2012 Q3 | 7.38 Million SEK | -20.38% |
| 2012 FY | 26.69 Million SEK | 187.86% |
| 2012 Q4 | 7.38 Million SEK | 0.0% |
| 2012 Q1 | 6.07 Million SEK | 0.0% |
| 2012 Q2 | 9.27 Million SEK | 52.56% |
| 2011 FY | 9.27 Million SEK | 48.46% |
| 2010 FY | 6.24 Million SEK | -18.69% |
| 2009 FY | 7.68 Million SEK | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Alzinova AB (publ) | 123.18 Million SEK | -513.652% |
| Amniotics AB (publ) | 26.08 Million SEK | -2797.922% |
| Asarina Pharma AB (publ) | 6.07 Million SEK | -12339.559% |
| BioArctic AB (publ) | 1.18 Billion SEK | 36.265% |
| Calliditas Therapeutics AB (publ) | 1.9 Billion SEK | 60.225% |
| Genovis AB (publ.) | 288.85 Million SEK | -161.705% |
| LIDDS AB (publ) | 17.65 Million SEK | -4181.801% |
| Magle Chemoswed Holding AB (publ) | 278.74 Million SEK | -171.198% |
| OncoZenge AB (publ) | 20.34 Million SEK | -3616.578% |
| Saniona AB (publ) | 64.14 Million SEK | -1078.542% |
| Simris Alg AB (publ) | 174.55 Million SEK | -333.081% |
| Vicore Pharma Holding AB (publ) | 496.24 Million SEK | -52.334% |
| AcouSort AB (publ) | 34.51 Million SEK | -2090.34% |
| Active Biotech AB (publ) | 44 Million SEK | -1618.073% |
| Camurus AB (publ) | 1.9 Billion SEK | 60.376% |
| Cantargia AB (publ) | 223.71 Million SEK | -237.913% |
| Scandinavian ChemoTech AB (publ) | 14.86 Million SEK | -4984.081% |
| Guard Therapeutics International AB (publ) | 85.22 Million SEK | -786.987% |
| Kancera AB (publ) | 65.64 Million SEK | -1051.611% |
| Karolinska Development AB (publ) | 1.25 Billion SEK | 39.927% |
| Lipum AB (publ) | 12.11 Million SEK | -6142.378% |
| Lipigon Pharmaceuticals AB (publ) | 33.6 Million SEK | -2149.723% |
| NextCell Pharma AB | 81.28 Million SEK | -829.967% |
| Xbrane Biopharma AB (publ) | 653.5 Million SEK | -15.676% |
| Xintela AB (publ) | 18.39 Million SEK | -4009.552% |
| Ziccum AB (publ) | 14.97 Million SEK | -4949.105% |
| Elicera Therapeutics AB (publ) | 30.17 Million SEK | -2405.39% |
| Modus Therapeutics Holding AB (publ) | 20.04 Million SEK | -3672.027% |
| Isofol Medical AB (publ) | 140.59 Million SEK | -437.673% |
| Xspray Pharma AB (publ) | 765.26 Million SEK | 1.217% |
| CombiGene AB (publ) | 120.61 Million SEK | -526.764% |
| Diamyd Medical AB (publ) | 217.03 Million SEK | -248.304% |
| Intervacc AB (publ) | 259.61 Million SEK | -191.186% |
| Alligator Bioscience AB (publ) | 118.45 Million SEK | -538.203% |
| Sprint Bioscience AB (publ) | 62.37 Million SEK | -1111.908% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 41.95 Million SEK | -1701.644% |
| Corline Biomedical AB | 100.1 Million SEK | -655.159% |
| IRLAB Therapeutics AB (publ) | 177.12 Million SEK | -326.8% |
| Bio-Works Technologies AB (publ) | 62.15 Million SEK | -1116.296% |
| Aptahem AB (publ) | 63.02 Million SEK | -1099.449% |
| Infant Bacterial Therapeutics AB (publ) | 351.33 Million SEK | -115.166% |
| Fluicell AB (publ) | 9.34 Million SEK | -7993.704% |
| Biovica International AB (publ) | 131.4 Million SEK | -475.271% |
| Spago Nanomedical AB (publ) | 52.98 Million SEK | -1326.728% |
| Abliva AB (publ) | 87.49 Million SEK | -763.955% |
| Egetis Therapeutics AB (publ) | 760.2 Million SEK | 0.559% |
| 2cureX AB (publ) | 16.62 Million SEK | -4447.08% |
| I-Tech AB | 152.44 Million SEK | -395.892% |
| Hansa Biopharma AB (publ) | 1.01 Billion SEK | 25.744% |
| Cyxone AB (publ) | 43.65 Million SEK | -1631.65% |
| ExpreS2ion Biotech Holding AB (publ) | 78.69 Million SEK | -860.647% |
| Biosergen AB | 7.2 Million SEK | -10397.875% |
| Nanologica AB (publ) | 77.42 Million SEK | -876.316% |
| SynAct Pharma AB | 228.01 Million SEK | -231.53% |
| Annexin Pharmaceuticals AB (publ) | 26.76 Million SEK | -2724.616% |
| BioInvent International AB (publ) | 1.4 Billion SEK | 46.01% |
| Stayble Therapeutics AB (publ) | 21.7 Million SEK | -3383.188% |
| Oncopeptides AB (publ) | 238.37 Million SEK | -217.123% |
| Pila Pharma AB (publ) | 8.45 Million SEK | -8840.887% |
| Ascelia Pharma AB (publ) | 87.07 Million SEK | -768.192% |
| Diagonal Bio AB (publ) | 28.5 Million SEK | -2551.719% |